181 related articles for article (PubMed ID: 16226118)
1. Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case.
Heiss S; Erdel M; Gunsilius E; Nachbaur D; Tzankov A
Hum Pathol; 2005 Oct; 36(10):1148-51. PubMed ID: 16226118
[TBL] [Abstract][Full Text] [Related]
2. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
3. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
[TBL] [Abstract][Full Text] [Related]
4. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
Bousquet M; Brousset P
Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
[No Abstract] [Full Text] [Related]
6. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A.
Dong HY; Wilkes S; Yang H
Am J Surg Pathol; 2011 May; 35(5):723-32. PubMed ID: 21415701
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
8. [Evolution to megakaryoblastic leukemia observed in myelodysplastic syndrome with erythrolekemia-like features].
Takai K; Sanada M; Shibuya H
Rinsho Ketsueki; 1992 Aug; 33(8):1071-6. PubMed ID: 1404864
[TBL] [Abstract][Full Text] [Related]
9. [Infant leukemia with t(1;22) presenting proliferation of erythroid and megakaryocytic cell lineages].
Oshima M; Fukushima T; Koike K; Hoshida C; Izumi I; Tsuchida M
Rinsho Ketsueki; 1999 Mar; 40(3):230-5. PubMed ID: 10222631
[TBL] [Abstract][Full Text] [Related]
10. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
12. Abnormal clones of megakaryocytes in myeloproliferative disorders.
Sato Y; Suda T
Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1705-18. PubMed ID: 3471029
[No Abstract] [Full Text] [Related]
13. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
14. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
15. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
16. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract][Full Text] [Related]
17. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.
Malherbe JA; Fuller KA; Arshad A; Nangalia J; Romeo G; Hall SL; Meehan KS; Guo B; Howman R; Erber WN
J Clin Pathol; 2016 Feb; 69(2):155-63. PubMed ID: 26290261
[TBL] [Abstract][Full Text] [Related]
18. ALDH, CA I, and CD2AP: novel, diagnostically useful immunohistochemical markers to identify erythroid precursors in bone marrow biopsy specimens.
Rollins-Raval MA; Fuhrer K; Marafioti T; Roth CG
Am J Clin Pathol; 2012 Jan; 137(1):30-8. PubMed ID: 22180476
[TBL] [Abstract][Full Text] [Related]
19. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
20. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.
Mark HF; Sotomayor EA; Nelson M; Chaves F; Sanger WG; Kaleem Z; Caughron SK
Exp Mol Pathol; 2006 Dec; 81(3):217-23. PubMed ID: 16959246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
